HomeCompareTCRR vs EPRT

TCRR vs EPRT: Dividend Comparison 2026

TCRR yields 135.14% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TCRR wins by $14.83M in total portfolio value
10 years
TCRR
TCRR
● Live price
135.14%
Share price
$1.48
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$14.90M
Annual income
$6,066,079.91
Full TCRR calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — TCRR vs EPRT

📍 TCRR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTCRREPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TCRR + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TCRR pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TCRR
Annual income on $10K today (after 15% tax)
$11,486.49/yr
After 10yr DRIP, annual income (after tax)
$5,156,167.92/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, TCRR beats the other by $5,144,972.70/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TCRR + EPRT for your $10,000?

TCRR: 50%EPRT: 50%
100% EPRT50/50100% TCRR
Portfolio after 10yr
$7.48M
Annual income
$3,039,625.39/yr
Blended yield
40.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

TCRR
Analyst Ratings
2
Buy
6
Hold
1
Sell
Consensus: Hold
Price Target
$5.00
+237.8% upside vs current
Range: $5.00 — $5.00
Altman Z
-7.2
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TCRR buys
0
EPRT buys
0
No recent congressional trades found for TCRR or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTCRREPRT
Forward yield135.14%3.97%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$14.90M$64.3K
Annual income after 10y$6,066,079.91$13,170.85
Total dividends collected$13.68M$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$5.00$35.50

Year-by-year: TCRR vs EPRT ($10,000, DRIP)

YearTCRR PortfolioTCRR Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$24,214$13,513.51$11,212$512.01+$13.0KTCRR
2$56,489$30,580.34$12,689$692.09+$43.8KTCRR
3$127,118$66,675.01$14,521$944.30+$112.6KTCRR
4$276,241$140,224.56$16,841$1,302.88+$259.4KTCRR
5$580,365$284,787.59$19,841$1,821.64+$560.5KTCRR
6$1,180,170$559,178.96$23,818$2,587.47+$1.16MTCRR
7$2,325,480$1,062,698.63$29,230$3,744.65+$2.30MTCRR
8$4,445,281$1,957,016.59$36,816$5,540.38+$4.41MTCRR
9$8,252,658$3,496,207.78$47,806$8,413.17+$8.20MTCRR
10$14,896,424$6,066,079.91$64,324$13,170.85+$14.83MTCRR

TCRR vs EPRT: Complete Analysis 2026

TCRRStock

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Full TCRR Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this TCRR vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TCRR vs SCHDTCRR vs JEPITCRR vs OTCRR vs KOTCRR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.